Amgen
attained a deal to invest in drug corporation
Horizon Therapeutics
for $116.50 a share in money.
In a statement, the organizations claimed the offer signifies a premium of about 47.9% to Horizon’s closing rate of $78.76 a share on Nov. 29, the working day prior to experiences of a attainable deal surfaced.
Amgen
attained a deal to invest in drug corporation
Horizon Therapeutics
for $116.50 a share in money.
In a statement, the organizations claimed the offer signifies a premium of about 47.9% to Horizon’s closing rate of $78.76 a share on Nov. 29, the working day prior to experiences of a attainable deal surfaced.
